reports
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udn...
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner KØBENHAVN, Danmark, 5. september 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 3.818.710 som følge af medarbejderes udnyttelse af tegningsoptioner. Kapitalforhøjelsen er sket uden fortegningsret for selskabets eksisterende aktionærer eller andre. Aktierne er tegnet kontant til følgende tegningskurser pr. aktie á nominelt DKK 10: 363.156 stk. aktier til DKK 206,82 og 18.715 stk. aktier til DKK 190,11. Det samlede provenu til ...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warran...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise COPENHAGEN, Denmark, September 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 363,156 shares at DKK 206.82 and 18,715 shares at DKK 190.11. The total procee...
Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelses...
Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelsestilbud til aktionærerne i Bavarian Nordic fra konsortium ledet af Nordic Capital og Permira MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, August 26, 2025 – Med henvisning til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) angående offentliggørelsen af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud ...
Publication of statement by the Board of Directors in respect of the t...
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, August 26, 2025 – With reference to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document concerning th...
Offentliggørelse af tilbudsdokument vedrørende overtagelsestilbud til ...
Offentliggørelse af tilbudsdokument vedrørende overtagelsestilbud til aktionærerne i Bavarian Nordic fra konsortium ledet af Nordic Capital og Permira og nedsættelse af minimumsbetingelsen for accept til 75% MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, August 26, 2025 – Med henvisning til selskabsmeddelelsen af 28. juli 2025 (nr. 21/2025) vedrørende indgåelsen af en bindende aftale mellem Innosera ...
Publication of offer document in respect of the takeover offer to the ...
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75% NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, August 26, 2025 – With reference to the announcement of 28 July 2025 (no. 21/2025) regarding the entering into of a binding agreement between Innosera ApS (the "Offeror")...
Bavarian Nordic offentliggør regnskab for første halvår 2025
Bavarian Nordic offentliggør regnskab for første halvår 2025 KØBENHAVN, Danmark, 22. august 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab samt rapporterede på begivenheder for første halvår 2025. Desuden offentliggør selskabet finanskalender for 2026. Omsætningen i første halvår steg med 33% til DKK 2.998 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 24% til DKK 1.386 mio. sammenlignet med første halvår 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabies og flåtbår...
Bavarian Nordic Announces First Half 2025 Results
Bavarian Nordic Announces First Half 2025 Results COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2025 and released its financial calendar for 2026. Revenue for the first half increased by 33% to DKK 2,998 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 24% to DKK 1,386 million compared to the first half of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines....
Bavarian Nordic afslutter salget af Priority Review Voucher og opjuste...
Bavarian Nordic afslutter salget af Priority Review Voucher og opjusterer de økonomiske forventninger til 2025 KØBENHAVN, Danmark, 31. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har afsluttet salget af sin Priority Review Voucher (PRV). Ved transaktionens afslutning har selskabet modtaget USD 160 mio. kontant. For yderligere informationer om transaktionen henvises til . Fratrukket royaltybetalingen til National Institutes of Health samt transaktionsomkostninger beløber nettoprovenuet sig til DKK 810 mio., der vil blive indregnet som andre driftsindtægter og ...
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher a...
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million. See for additional information about the PRV sale. After deduction of royalties to the National Institutes of Health and transaction costs, the net proceeds amount to DKK 810 million, which will be recognized as other operating income, and will therefore ...
Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant fr...
Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant frivilligt anbefalet købstilbud vedrørende Bavarian Nordic MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION KØBENHAVN, Danmark, 28. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) har i dag offentliggjort, at selskabet har indgået en offentliggørelsesaftale med Innosera ApS ("Tilbudsgiver"), et nystiftet selskab kontrolleret af Nordic Capit...
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recomm...
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, July 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) (“Bavarian Nordic”) announced today that it has entered into an announcement agreement with Innosera ApS (the “Offeror”), a newly formed company controlled by Nordic Capital Fund XI1 and funds managed and advised by...
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a consortium consisting of Nordic Capital and Permira. Bavarian Nordic A/S can confirm that we have been in discussions with Nordic Capital and Permira regarding a potential takeover offer for Bavarian Nordic A/S by Nordic Capital and Permira. As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic ...
Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunya...
Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgenne...
Bavarian Nordic Receives Acceptance from Health Canada for Review of t...
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is comp...
Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk...
Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land Gentagen ordre fra unavngivet europæisk land til styrkelse af det offentlige beredskab.Sammen med andre nylige ordrer fra ikke-europæiske lande har selskabet nu sikret kontrakter for mere end DKK 3.000 mio. i Public Preparedness-forretningen i 2025, og rammer dermed det forventede interval for dette forretningsområde. KØBENHAVN, Danmark, 9. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har modtaget en kontrakt til en værdi på over DKK 200 mio. på levering af MVA-BN® koppe-/mpoxvaccine ti...
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with ...
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 million in contracts in the Public Preparedness business in 2025, thus entering the targeted guidance interval for this business. COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a...
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio. KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse med de amerikanske sundhedsmyndigheders godkendelse af chikungunyavaccinen VIMKUNYA™ til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. I henhold til en licensaftale, der blev overdraget til Bavarian Nordic i forbindelse med opkøbet af ...
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 ...
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older. Pursuant to a license agreement assumed upon acquisit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.